Research

Hormonal

GLP-1 receptor agonist therapy for obesity effectively supports weight loss and improves quality of life, but long-term sustainability is undermined by high medication costs, inadequate multidisciplinary support, and significant side effects leading to discontinuation.

GLP-1 medications like Tirzepatide and Semaglutide are effective for weight loss and improving quality of life for many users. However, long-term success is not guaranteed. High costs and side effects are the main reasons people stop treatment. If you are considering or using these medications, be aware that discontinuation often leads to weight regain. Ensure you have a plan for managing costs and side effects, and consider seeking multidisciplinary support (dietary, psychological) to improve adherence and sustainability.

ModerateQualifiesMEDIUM confidence
While GLP-1RA treatment effectively supported weight goals, sustainability is undermined by high costs, inadequate holistic support, and side-effect burden.
Alex Griffiths et al. · medRxiv · 2025

Why this rating

Cross-sectional survey of real-world users; lacks control group and long-term follow-up data.

Source

Exploring real-world user experiences of GLP-1 receptor agonist therapy for obesity treatment, and barriers and motivators to adherence

Alex Griffiths et al. · medRxiv · 2025

DOI 10.64898/2025.12.11.25342052

preprint · n=624Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →